• 1
    International Agency for Research on Cancer (IARC). IARC Handbooks of Cancer Prevention, Vol. 10: Cervix Cancer Screening. Lyon: International Agency for Research on Cancer Press, 2005.
  • 2
    Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Giubilato P, et al. Process performance of cervical screening programmes in Europe. Eur J Cancer 2009;45:265970.
  • 3
    Rebolj M, van Ballegooijen M, Berkers LM, Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2007;120:80612.
  • 4
    Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making 2007;27:41422.
  • 5
    Tombola Group. Cytological surveillance compared with immediate referral for colposcopy in management of women with low grade cervical abnormalities: multicentre randomised controlled trial. Br Med J 2009;339:b2546.
  • 6
    The ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:138392.
  • 7
    Melnikow J, Nuovo J, Paliescheskey M. Management choices for patients with “squamous atypia” on Papanicolaou smear. A toss up? Med Care 1996;34:33647.
  • 8
    Tombola Group. Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study. Br Med J 2009;339:b2549.
  • 9
    Prendiville W, Walker P. Every woman with an abnormal cervical smear should not be referred for colposcopy: debate. Clin Obstet Gynecol 1995;38:5929.
  • 10
    Flannelly G, Kitchener H. Every woman with an abnormal cervical smear should be referred for treatment: debate. Clin Obstet Gynecol 1995;38:58591.
  • 11
    Jones MH, Singer A, Jenkins D. The mildly abnormal cervical smear: patient anxiety and choice of management. J R Soc Med 1996;89:25760.
  • 12
    Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. Br Med J 2004;328:1293.
  • 13
    Melnikow J, Birch S. Human papillomavirus triage of atypical squamous cells of undetermined significance: cost-effective, but at what cost? J Natl Cancer Inst 2006;98:823.
  • 14
    Ferris DG, Kriegel D, Cote L, Litaker M, Woodward L. Women’s triage and management preferences for cervical cytologic reports demonstrating atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions. Arch Fam Med 1997;6:34853.
  • 15
    Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26:K2941.
  • 16
    Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:176472.
  • 17
    Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del MA, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:24957.
  • 18
    Lynge E, Rebolj M. Primary HPV screening for cervical cancer prevention: results from European trials. Nat Rev Clin Oncol 2009;6:699706.
  • 19
    Peters T, Somerset M, Baxter K, Wilkinson C. Anxiety among women with mild dyskaryosis: a randomized trial of an educational intervention. Br J Gen Pract 1999;49:34852.
  • 20
    Huang AJ, Perez-Stable EJ, Kim SE, Wong ST, Kaplan CP, Walsh JM, et al. Preferences for human papillomavirus testing with routine cervical cancer screening in diverse older women. J Gen Intern Med 2008;23:13249.
  • 21
    McCaffery KJ, Irwig L, Chan SF, Macaskill P, Barratt A, Lewicka M, et al. HPV testing versus repeat Pap testing for the management of a minor abnormal Pap smear: evaluation of a decision aid to support informed choice. Patient Educ Couns 2008;73:47381.
  • 22
    Whynes DK, Woolley C, Philips Z. Management of low-grade cervical abnormalities detected at screening: which method do women prefer? Cytopathology 2008;19:35562.
  • 23
    Howard K, Salkeld G, McCaffery K, Irwig L. HPV triage testing or repeat Pap smear for the management of atypical squamous cells (ASCUS) on Pap smear: is there evidence of process utility? Health Econ 2008;17:593605.
  • 24
    Melnikow J, Kuppermann M, Birch S, Chan BK, Nuovo J. Management of the low-grade abnormal Pap smear: what are women’s preferences? J Fam Pract 2002;51:84955.
  • 25
    Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009;13:iiv.
  • 26
    Meana M, Stewart DE, Lickrish GM, Murphy J, Rosen B. Patient preference for the management of mildly abnormal Papanicolaou smears. J Womens Health Gend Based Med 1999;8:9417.
  • 27
    Brown L, Ritvo P, Howlett R, Cotterchio M, Matthew A, Rosen B, et al. Attitudes toward HPV testing: interview findings from a random sample of women in Ontario, Canada. Health Care Women Int 2007;28:78298.
  • 28
    Philips Z, Avis M, Whynes DK. Introducing HPV triage into the English cervical cancer screening program: consequences for participation. Women Health 2006;43:1734.
  • 29
    Kitchener HC, Burns S, Nelson L, Myers AJ, Fletcher I, Desai M, et al. A randomised controlled trial of cytological surveillance versus patient choice between surveillance and colposcopy in managing mildly abnormal cervical smears. BJOG 2004;111:6370.
  • 30
    Le T, Hicks W, Menard C, Boyd D, Hewson T, Hopkins L, et al. Human papilloma virus testing knowledge and attitudes among women attending colposcopy clinic with ASCUS/LGSIL pap smears. J Obstet Gynaecol Can 2004;26:78892.
  • 31
    Patel M, Guido R, Chang JC, Meyn LA. What are patient preferences for follow-up after low-grade cervical intraepithelial neoplasia? J Low Genit Tract Dis 2008;12:1226.
  • 32
    Orbell S, Hagger M, Brown V, Tidy J. Appraisal theory and emotional sequelae of first visit to colposcopy following an abnormal cervical screening result. Br J Health Psychol 2004;9:53355.
  • 33
    Wordsworth S, Ryan M, Skatun D, Waugh N. Women’s preferences for cervical cancer screening: a study using a discrete choice experiment. Int J Technol Assess Health Care 2006;22:34450.
  • 34
    McCaffery K, Irwig L. Australian women’s needs and preferences for information about human papillomavirus in cervical screening. J Med Screen 2005;12:13441.
  • 35
    Naik R, Abang-Mohammed K, Tjalma WA, Nordin A, de Barros LA, Cross PA, et al. The feasibility of a one-stop colposcopy clinic in the management of women with low grade smear abnormalities: a prospective study. Eur J Obstet Gynecol Reprod Biol 2001;98:2058.
  • 36
    Lonky NM, Hunter MI, Sadeghi M, Edwards G, Bajamundi K, Monk BJ. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program. J Low Genit Tract Dis 2007;11:25864.
  • 37
    Basen-Engquist K, Fouladi RT, Cantor SB, Shinn E, Sui D, Sharman M, et al. Patient assessment of tests to detect cervical cancer. Int J Technol Assess Health Care 2007;23:2407.
  • 38
    Kavanagh AM, Broom DH. Women’s understanding of abnormal cervical smear test results: a qualitative interview study. Br Med J 1997;314:138891.
  • 39
    Birch S, Melnikow J, Kuppermann M. Conservative versus aggressive follow up of mildly abnormal Pap smears: testing for process utility. Health Econ 2003;12:87984.
  • 40
    Waller J, McCaffery K, Kitchener H, Nazroo J, Wardle J. Women’s experiences of repeated HPV testing in the context of cervical cancer screening: a qualitative study. Psychooncology 2007;16:196204.
  • 41
    McCaffery KJ, Irwig L, Turner R, Chan SF, Macaskill P, Lewicka M, et al. Psychosocial outcomes of three triage methods for the management of borderline abnormal cervical smears: an open randomised trial. Br Med J 2010;340:b4491.
  • 42
    Hartz LE, Fenaughty AM. Management choice and adherence to follow-up after colposcopy in women with cervical intraepithelial neoplasia 1. Obstet Gynecol 2001;98:6749.
  • 43
    Philips Z, Avis M, Whynes DK. Knowledge of cervical cancer and screening among women in east-central England. Int J Gynecol Cancer 2005;15:63945.
  • 44
    Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:147888.
  • 45
    Kitchener HC, Fletcher I, Roberts C, Wheeler P, Almonte M, Maguire P. The psychosocial impact of human papillomavirus testing in primary cervical screening – a study within a randomized trial. Int J Gynecol Cancer 2008;18:7438.
  • 46
    McCaffery K, Forrest S, Waller J, Desai M, Szarewski A, Wardle J. Attitudes towards HPV testing: a qualitative study of beliefs among Indian, Pakistani, African-Caribbean and white British women in the UK. Br J Cancer 2003;88:426.
  • 47
    McCaffery K, Waller J, Nazroo J, Wardle J. Social and psychological impact of HPV testing in cervical screening: a qualitative study. Sex Transm Infect 2006;82:16974.
  • 48
    Perrin KK, Daley EM, Naoom SF, Packing-Ebuen JL, Rayko HL, McFarlane M, et al. Women’s reactions to HPV diagnosis: insights from in-depth interviews. Women Health 2006;43:93110.
  • 49
    Conaglen HM, Hughes R, Conaglen JV, Morgan J. A prospective study of the psychological impact on patients of first diagnosis of human papillomavirus. Int J STD AIDS 2001;12:6518.
  • 50
    NHS Cervical Screening Programme. Cervical Screening: Pocket Guide. 2009. []. Last accessed 2 May 2011.
  • 51
    NHS Cervical Screening Programme. HPV Sentinel Sites Implementation Project. 2010. []. Last accessed 1 June 2011.
  • 52
    Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197:34655.
  • 53
    Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up. Br J Cancer 2005;92:9904.
  • 54
    Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:8899.
  • 55
    Sharp L, Cotton S, Cochran C, Gray N, Little J, Neal K, et al. After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial. BJOG 2009;116:150614.
  • 56
    Rebolj M, Bonde J, Njor SH, Lynge E. Human papillomavirus testing in primary cervical screening and the cut-off for Hybrid Capture 2 tests: systematic review. Br Med J 2011;342:d2757.
  • 57
    Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjanen K, Halfon P, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer 2010;129:691701.
  • 58
    Kim SE, Perez-Stable EJ, Wong S, Gregorich S, Sawaya GF, Walsh JM, et al. Association between cancer risk perception and screening behavior among diverse women. Arch Intern Med 2008;168:72834.